SeaCrest Wealth Management LLC Has $953,000 Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

SeaCrest Wealth Management LLC trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,940 shares of the medical equipment provider’s stock after selling 41 shares during the period. SeaCrest Wealth Management LLC’s holdings in Intuitive Surgical were worth $953,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Capital Research Global Investors purchased a new stake in Intuitive Surgical in the 1st quarter worth approximately $374,390,000. Vanguard Group Inc. boosted its position in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock valued at $356,524,000 after purchasing an additional 302,382 shares during the last quarter. Strategic Financial Concepts LLC increased its position in Intuitive Surgical by 40,221.4% in the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after purchasing an additional 265,461 shares during the last quarter. Finally, GQG Partners LLC purchased a new stake in shares of Intuitive Surgical during the 1st quarter worth about $99,523,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on ISRG. Piper Sandler boosted their price target on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Citigroup increased their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Robert W. Baird lifted their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. JPMorgan Chase & Co. increased their target price on shares of Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, Royal Bank of Canada boosted their price target on Intuitive Surgical from $515.00 to $525.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $474.16.

Intuitive Surgical Trading Down 0.4 %

ISRG opened at $476.59 on Thursday. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.48. The business has a 50 day moving average of $482.49 and a 200-day moving average of $436.65. The stock has a market capitalization of $169.05 billion, a price-to-earnings ratio of 86.03, a P/E/G ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the company earned $1.18 EPS. Equities analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,414,931.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at $5,441,507.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert Desantis sold 1,413 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,414,931.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 over the last ninety days. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.